Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Kang UJ, Nakamura K, Zhuang X. Neurology 2022;99:258-259.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kang UJ, Nakamura K, Zhuang X. Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology 2022;99:258-259.
PMID: 35940895